[
  {
    "ts": null,
    "headline": "Stock Futures Drift Higher Ahead of Jobs, Inflation Data",
    "summary": "Investors are awaiting the release of the January jobs report, which was delayed a week because of the shutdown, and the CPI data for January.",
    "url": "https://finnhub.io/api/news?id=de2744169e13dc83bcc73fdbd19988103f2db1d9bed35ab3f2e17d7d2fc03e19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770592920,
      "headline": "Stock Futures Drift Higher Ahead of Jobs, Inflation Data",
      "id": 138397536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Investors are awaiting the release of the January jobs report, which was delayed a week because of the shutdown, and the CPI data for January.",
      "url": "https://finnhub.io/api/news?id=de2744169e13dc83bcc73fdbd19988103f2db1d9bed35ab3f2e17d7d2fc03e19"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Reshapes Inflammation Portfolio As Investors Weigh Cash And Pipeline Shifts",
    "summary": "Amgen ended its collaboration with Kyowa Kirin on the experimental eczema drug rocatinlimab. The company received an FDA request to withdraw Tavneos, a treatment for rare blood vessel disease, due to clinical trial data concerns. These moves point to a refocus of Amgen's therapeutic portfolio in inflammation and rare diseases. For investors tracking NasdaqGS:AMGN, these decisions come with the stock at $384.32 and strong recent share performance, including a 12.4% return over the past week...",
    "url": "https://finnhub.io/api/news?id=66a36c49c085c1edc6e9bc9e00cc4fd0bd2ad831d7b87ebedfe2503358de4fcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770573929,
      "headline": "Amgen Reshapes Inflammation Portfolio As Investors Weigh Cash And Pipeline Shifts",
      "id": 138395472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen ended its collaboration with Kyowa Kirin on the experimental eczema drug rocatinlimab. The company received an FDA request to withdraw Tavneos, a treatment for rare blood vessel disease, due to clinical trial data concerns. These moves point to a refocus of Amgen's therapeutic portfolio in inflammation and rare diseases. For investors tracking NasdaqGS:AMGN, these decisions come with the stock at $384.32 and strong recent share performance, including a 12.4% return over the past week...",
      "url": "https://finnhub.io/api/news?id=66a36c49c085c1edc6e9bc9e00cc4fd0bd2ad831d7b87ebedfe2503358de4fcd"
    }
  },
  {
    "ts": null,
    "headline": "The Dow Surged Past 50,000. How Caterpillar and These Other Stocks Got It There.",
    "summary": "The broader market passed a significant milestone thanks to big gains for stocks outside of tech. Goldman Sachs and Caterpillar are examples.",
    "url": "https://finnhub.io/api/news?id=173883256409e9c3866072515ae3468d7fea5fbd2746e9d535f472b3aa735587",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770408480,
      "headline": "The Dow Surged Past 50,000. How Caterpillar and These Other Stocks Got It There.",
      "id": 138379480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The broader market passed a significant milestone thanks to big gains for stocks outside of tech. Goldman Sachs and Caterpillar are examples.",
      "url": "https://finnhub.io/api/news?id=173883256409e9c3866072515ae3468d7fea5fbd2746e9d535f472b3aa735587"
    }
  }
]